首页> 美国卫生研究院文献>Cancer Medicine >Strategies for discovery and validation of methylated and hydroxymethylated DNA biomarkers
【2h】

Strategies for discovery and validation of methylated and hydroxymethylated DNA biomarkers

机译:发现和验证甲基化和羟甲基化DNA生物标记物的策略

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

DNA methylation, consisting of the addition of a methyl group at the fifth-position of cytosine in a CpG dinucleotide, is one of the most well-studied epigenetic mechanisms in mammals with important functions in normal and disease biology. Disease-specific aberrant DNA methylation is a well-recognized hallmark of many complex diseases. Accordingly, various studies have focused on characterizing unique DNA methylation marks associated with distinct stages of disease development as they may serve as useful biomarkers for diagnosis, prognosis, prediction of response to therapy, or disease monitoring. Recently, novel CpG dinucleotide modifications with potential regulatory roles such as 5-hydroxymethylcytosine, 5-formylcytosine, and 5-carboxylcytosine have been described. These potential epigenetic marks cannot be distinguished from 5-methylcytosine by many current strategies and may potentially compromise assessment and interpretation of methylation data. A large number of strategies have been described for the discovery and validation of DNA methylation-based biomarkers, each with its own advantages and limitations. These strategies can be classified into three main categories: restriction enzyme digestion, affinity-based analysis, and bisulfite modification. In general, candidate biomarkers are discovered using large-scale, genome-wide, methylation sequencing, and/or microarray-based profiling strategies. Following discovery, biomarker performance is validated in large independent cohorts using highly targeted locus-specific assays. There are still many challenges to the effective implementation of DNA methylation-based biomarkers. Emerging innovative methylation and hydroxymethylation detection strategies are focused on addressing these gaps in the field of epigenetics. The development of DNA methylation- and hydroxymethylation-based biomarkers is an exciting and rapidly evolving area of research that holds promise for potential applications in diverse clinical settings.
机译:DNA甲基化由CpG二核苷酸中胞嘧啶第五个位置的甲基组成,是哺乳动物中研究最广的表观遗传机制之一,在正常和疾病生物学中具有重要功能。疾病特异性异常DNA甲基化是许多复杂疾病的公认标志。因此,各种研究集中于表征与疾病发展的不同阶段相关的独特DNA甲基化标记,因为它们可以用作诊断,预后,对治疗反应的预测或疾病监测的有用生物标记。最近,已经描述了具有潜在调节作用的新的CpG二核苷酸修饰,例如5-羟甲基胞嘧啶,5-甲酰基胞嘧啶和5-羧胞嘧啶。这些潜在的表观遗传标记无法通过许多当前策略与5-甲基胞嘧啶区分开,并且可能潜在地损害甲基化数据的评估和解释。已经描述了用于发现和验证基于DNA甲基化的生物标记物的大量策略,每种策略都有其自身的优点和局限性。这些策略可分为三大类:限制酶消化,基于亲和力的分析和亚硫酸氢盐修饰。通常,使用大规模,全基因组,甲基化测序和/或基于微阵列的分析策略发现候选生物标记。发现后,使用高度针对性的基因座特异性测定法在大型独立队列中验证了生物标志物的性能。有效实施基于DNA甲基化的生物标志物仍然存在许多挑战。新兴的甲基化和羟甲基化检测策略致力于解决表观遗传学领域的这些空白。基于DNA甲基化和羟甲基化的生物标记物的开发是一个令人兴奋且迅速发展的研究领域,它有望在各种临床环境中得到潜在的应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号